<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35327621</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2218-273X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomolecules</Title>
          <ISOAbbreviation>Biomolecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kv7 Channels in Cyclic-Nucleotide Dependent Relaxation of Rat Intra-Pulmonary Artery.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">429</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12030429</ELocationID>
        <Abstract>
          <AbstractText>Pulmonary hypertension is treated with drugs that stimulate cGMP or cAMP signalling. Both nucleotides can activate Kv7 channels, leading to smooth muscle hyperpolarisation, reduced Ca<sup>2+</sup> influx and relaxation. Kv7 activation by cGMP contributes to the pulmonary vasodilator action of nitric oxide, but its contribution when dilation is evoked by the atrial natriuretic peptide (ANP) sensitive guanylate cyclase, or cAMP, is unknown. Small vessel myography was used to investigate the ability of Kv7 channel blockers to interfere with pulmonary artery relaxation when cyclic nucleotide pathways were stimulated in different ways. The pan-Kv7 blockers, linopirdine and XE991, caused substantial inhibition of relaxation evoked by NO donors and ANP, as well as endothelium-dependent dilators, the guanylate cyclase stimulator, riociguat, and the phosphodiesterase-5 inhibitor, sildenafil. Maximum relaxation was reduced without a change in sensitivity. The blockers had relatively little effect on cAMP-mediated relaxation evoked by forskolin, isoprenaline or treprostinil. The Kv7.1-selective blocker, HMR1556, had no effect on cGMP or cAMP-dependent relaxation. Western blot analysis demonstrated the presence of Kv7.1 and Kv7.4 proteins, while selective activators of Kv7.1 and Kv7.4 homomeric channels, but not Kv7.5, caused pulmonary artery relaxation. It is concluded that Kv7.4 channels contribute to endothelium-dependent dilation and the effects of drugs that act by stimulating cGMP, but not cAMP, signalling.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Al-Chawishly</LastName>
            <ForeName>Mohammed</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-7540-9837</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacy and Optometry, Faculty of Biology Medicine and Health, University of Manchester, Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pharmacology and Toxicology Department, College of Pharmacy, Hawler Medical University, Erbil P.O. Box 178, Iraq.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loveland</LastName>
            <ForeName>Oliver</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0001-7706-1344</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacy and Optometry, Faculty of Biology Medicine and Health, University of Manchester, Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gurney</LastName>
            <ForeName>Alison M</ForeName>
            <Initials>AM</Initials>
            <Identifier Source="ORCID">0000-0001-8821-1088</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacy and Optometry, Faculty of Biology Medicine and Health, University of Manchester, Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomolecules</MedlineTA>
        <NlmUniqueID>101596414</NlmUniqueID>
        <ISSNLinking>2218-273X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009712">Nucleotides, Cyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>85637-73-6</RegistryNumber>
          <NameOfSubstance UI="D009320">Atrial Natriuretic Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.6.1.2</RegistryNumber>
          <NameOfSubstance UI="D006162">Guanylate Cyclase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H2D2X058MU</RegistryNumber>
          <NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009320" MajorTopicYN="Y">Atrial Natriuretic Factor</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006162" MajorTopicYN="N">Guanylate Cyclase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009712" MajorTopicYN="N">Nucleotides, Cyclic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011651" MajorTopicYN="Y">Pulmonary Artery</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Kv7 channel</Keyword>
        <Keyword MajorTopicYN="Y">XE991</Keyword>
        <Keyword MajorTopicYN="Y">cAMP</Keyword>
        <Keyword MajorTopicYN="Y">cGMP</Keyword>
        <Keyword MajorTopicYN="Y">linopirdine</Keyword>
        <Keyword MajorTopicYN="Y">pulmonary artery</Keyword>
        <Keyword MajorTopicYN="Y">riociguat</Keyword>
        <Keyword MajorTopicYN="Y">sildenafil</Keyword>
        <Keyword MajorTopicYN="Y">treprostinil</Keyword>
        <Keyword MajorTopicYN="Y">vasodilation</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>1</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35327621</ArticleId>
        <ArticleId IdType="pmc">PMC8946781</ArticleId>
        <ArticleId IdType="doi">10.3390/biom12030429</ArticleId>
        <ArticleId IdType="pii">biom12030429</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Montani D., Chaumais M.-C., Guignabert C., Günther S., Girerd B., Jais X., Algalarrondo V., Price L.C., Savale L., Sitbon O., et al.  Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 2014;141:172–191. doi: 10.1016/j.pharmthera.2013.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2013.10.002</ArticleId>
            <ArticleId IdType="pubmed">24134901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkins M.R., Aman J., Harbaum L., Ulrich A., Wharton J., Rhodes C. Recent advances in pulmonary arterial hypertension. F1000Research. 2018;7:1128. doi: 10.12688/f1000research.14984.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12688/f1000research.14984.1</ArticleId>
            <ArticleId IdType="pmc">PMC6058465</ArticleId>
            <ArticleId IdType="pubmed">30079232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nausch L.W.M., Ledoux J., Bonev A.D., Nelson M.T., Dostmann W.R. Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors. Proc. Natl. Acad. Sci. USA. 2008;105:365–370. doi: 10.1073/pnas.0710387105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0710387105</ArticleId>
            <ArticleId IdType="pmc">PMC2224218</ArticleId>
            <ArticleId IdType="pubmed">18165313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clapp L.H., Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat. 2015;120:56–71. doi: 10.1016/j.prostaglandins.2015.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.prostaglandins.2015.04.007</ArticleId>
            <ArticleId IdType="pubmed">25917921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chester A.H., Yacoub M.H., Moncada S. Nitric oxide and pulmonary arterial hypertension. Glob. Cardiol. Sci. Pr. 2017;2017:14. doi: 10.21542/gcsp.2017.14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21542/gcsp.2017.14</ArticleId>
            <ArticleId IdType="pmc">PMC5871404</ArticleId>
            <ArticleId IdType="pubmed">29644226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi S., Balan P., Gurney A.M. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir. Res. 2006;7:31. doi: 10.1186/1465-9921-7-31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1465-9921-7-31</ArticleId>
            <ArticleId IdType="pmc">PMC1395307</ArticleId>
            <ArticleId IdType="pubmed">16504007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi S., Sedivy V., Hodyc D., Herget J., Gurney A.M. KCNQ Modulators Reveal a Key Role for KCNQ Potassium Channels in Regulating the Tone of Rat Pulmonary Artery Smooth Muscle. J. Pharmacol. Exp. Ther. 2009;329:368–376. doi: 10.1124/jpet.108.147785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.108.147785</ArticleId>
            <ArticleId IdType="pmc">PMC2684066</ArticleId>
            <ArticleId IdType="pubmed">19151245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chadha P.S., Zunke F., Davis A.J., Jepps T.A., Linders J.T., Schwake M., Towart R., Greenwood I.A. Pharmacological dissection of Kv7.1 channels in systemic and pulmonary arteries. J. Cereb. Blood Flow Metab. 2012;166:1377–1387. doi: 10.1111/j.1476-5381.2012.01863.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2012.01863.x</ArticleId>
            <ArticleId IdType="pmc">PMC3417453</ArticleId>
            <ArticleId IdType="pubmed">22251082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedivy V., Joshi S., Ghaly Y., Mizera R., Zaloudikova M., Brennan S., Novotna J., Herget J., Gurney A.M. Role of Kv7 channels in responses of the pulmonary circulation to hypoxia. Am. J. Physiol. Cell. Mol. Physiol. 2015;308:L48–L57. doi: 10.1152/ajplung.00362.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00362.2013</ArticleId>
            <ArticleId IdType="pmc">PMC4281702</ArticleId>
            <ArticleId IdType="pubmed">25361569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Der Horst J., Greenwood I.A., Jepps T.A. Cyclic AMP-Dependent Regulation of Kv7 Voltage-Gated Potassium Channels. Front. Physiol. 2020;11:727. doi: 10.3389/fphys.2020.00727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2020.00727</ArticleId>
            <ArticleId IdType="pmc">PMC7338754</ArticleId>
            <ArticleId IdType="pubmed">32695022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stott J.B., Barrese V., Jepps T.A., Leighton E.V., Greenwood I.A. Contribution of Kv7 Channels to Natriuretic Peptide Mediated Vasodilation in Normal and Hypertensive Rats. Hypertension. 2015;65:676–682. doi: 10.1161/HYPERTENSIONAHA.114.04373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.114.04373</ArticleId>
            <ArticleId IdType="pubmed">25547342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mondéjar-Parreño G., Moral-Sanz J., Barreira B., De la Cruz A., Gonzalez T., Callejo M., Esquivel-Ruiz S., Morale-Cano D., Moreno L., Valenzuela C., et al.  Activation of Kv7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation. J. Cereb. Blood Flow Metab. 2019;176:2131–2145. doi: 10.1111/bph.14662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.14662</ArticleId>
            <ArticleId IdType="pmc">PMC6555858</ArticleId>
            <ArticleId IdType="pubmed">30883701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chadha P.S., Zunke F., Zhu H.-L., Davis A.J., Jepps T.A., Olesen S.P., Cole W.C., Moffatt J.D., Greenwood I.A. Reduced KCNQ4-Encoded Voltage-Dependent Potassium Channel Activity Underlies Impaired β-Adrenoceptor–Mediated Relaxation of Renal Arteries in Hypertension. Hypertension. 2012;59:877–884. doi: 10.1161/HYPERTENSIONAHA.111.187427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.111.187427</ArticleId>
            <ArticleId IdType="pubmed">22353613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chadha P.S., Jepps T.A., Carr G., Stott J.B., Zhu H.-L., Cole W.C., Greenwood I.A. Contribution of Kv7.4/Kv7.5 Heteromers to Intrinsic and Calcitonin Gene-Related Peptide–Induced Cerebral Reactivity. Arter. Thromb. Vasc. Biol. 2014;34:887–893. doi: 10.1161/ATVBAHA.114.303405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.114.303405</ArticleId>
            <ArticleId IdType="pubmed">24558103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S., Yang Y., Tanner M.A., Li M., Hill M. Heterogeneity in Kv7 channel function in the cerebral and coronary circulation. Microcirculation. 2015;22:109–121. doi: 10.1111/micc.12183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/micc.12183</ArticleId>
            <ArticleId IdType="pmc">PMC4409830</ArticleId>
            <ArticleId IdType="pubmed">25476662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani B., Robakowski C., Brueggemann L.I., Cribbs L.L., Tripathi A., Majetschak M., Byron K.L. Kv7.5 Potassium Channel Subunits Are the Primary Targets for PKA-Dependent Enhancement of Vascular Smooth Muscle Kv7 Currents. Mol. Pharmacol. 2016;89:323–334. doi: 10.1124/mol.115.101758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.115.101758</ArticleId>
            <ArticleId IdType="pmc">PMC4767407</ArticleId>
            <ArticleId IdType="pubmed">26700561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales-Cano D., Moreno L., Barreira B., Pandolfi R., Chamorro V., Jimenez R., Villamor E., Duarte J., Perez-Vizcaino F., Cogolludo A. Kv7 channels critically determine coronary artery reactivity: Left-right differences and down-regulation by hyperglycaemia. Cardiovasc. Res. 2015;106:98–108. doi: 10.1093/cvr/cvv020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvv020</ArticleId>
            <ArticleId IdType="pubmed">25616413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stott J., Greenwood I. Complex role of Kv7 channels in cGMP and cAMP-mediated relaxations. Channels. 2015;9:117–118. doi: 10.1080/19336950.2015.1046732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19336950.2015.1046732</ArticleId>
            <ArticleId IdType="pmc">PMC4594225</ArticleId>
            <ArticleId IdType="pubmed">25975669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byron K.L., Brueggemann L.I. Kv7 potassium channels as signal transduction intermediates in the control of microvascular tone. Microcirculation. 2018;25:e12419. doi: 10.1111/micc.12419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/micc.12419</ArticleId>
            <ArticleId IdType="pubmed">28976052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stott J.B., Barrese V., Greenwood I.A. Kv7 Channel Activation Underpins EPAC-Dependent Relaxations of Rat Arteries. Arter. Thromb. Vasc. Biol. 2016;36:2404–2411. doi: 10.1161/ATVBAHA.116.308517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.116.308517</ArticleId>
            <ArticleId IdType="pmc">PMC5467728</ArticleId>
            <ArticleId IdType="pubmed">27789473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brueggemann L.I., Cribbs L.L., Byron K.L. Heteromeric channels formed from alternating Kv7.4 and Kv7.5 α-subunits display biophysical, regulatory, and pharmacological characteristics of smooth muscle M-currents. Front. Physiol. 2020;11:992. doi: 10.3389/fphys.2020.00992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2020.00992</ArticleId>
            <ArticleId IdType="pmc">PMC7434985</ArticleId>
            <ArticleId IdType="pubmed">32903335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melzig M.F., Alasbahi R.H. Forskolin and derivatives as tools for studying the role of cAMP. Pharmazie. 2012;67:5–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22393824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim H., Dey S.K. Minireview: A Novel Pathway of Prostacyclin Signaling—Hanging Out with Nuclear Receptors. Endocrinology. 2002;143:3207–3210. doi: 10.1210/en.2002-220159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2002-220159</ArticleId>
            <ArticleId IdType="pubmed">12193530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington L.S., Moreno L., Reed A., Wort S.J., Desvergne B., Garland C., Zhao L., Mitchell J.A. The PPARβ/δAgonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with Hypoxia-Induced Pulmonary Hypertension. PLoS ONE. 2010;5:e9526.  doi: 10.1371/journal.pone.0009526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0009526</ArticleId>
            <ArticleId IdType="pmc">PMC2831997</ArticleId>
            <ArticleId IdType="pubmed">20209098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchikami C., Murakami K., Tajima K., Homan J., Kosugi K., Kuramoto K., Oka M., Kuwano K. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. Eur. J. Pharmacol. 2017;795:75–83. doi: 10.1016/j.ejphar.2016.11.057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2016.11.057</ArticleId>
            <ArticleId IdType="pubmed">27919660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittle B.J., Silverstein A.M., Mottola D.M., Clapp L. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. Biochem. Pharmacol. 2012;84:68–75. doi: 10.1016/j.bcp.2012.03.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2012.03.012</ArticleId>
            <ArticleId IdType="pubmed">22480736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corboz M.R., Salvail W., Gagnon S., LaSala D., Laurent C.E., Salvail D., Chen K.-J., Cipolla D., Perkins W.R., Chapman R.W. Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts. Prostaglandins Other Lipid Mediat. 2021;152:106486. doi: 10.1016/j.prostaglandins.2020.106486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.prostaglandins.2020.106486</ArticleId>
            <ArticleId IdType="pubmed">33011365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salata J.J., Jurkiewicz N.K., Wang J., Evans B.E., Orme H.T., Sanguinetti M.C. A Novel Benzodiazepine that Activates Cardiac Slow Delayed Rectifier K+ Currents. Mol. Pharmacol. 1998;54:220–230. doi: 10.1124/mol.54.1.220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.54.1.220</ArticleId>
            <ArticleId IdType="pubmed">9658209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattmann M.E., Yu H., Lin Z., Xu K., Huang X., Long S., Wu M., McManus O.B., Engers D.W., Le U.M., et al.  Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective Kv7.1 (KCNQ1) potassium channel activator. Bioorganic Med. Chem. Lett. 2012;22:5936–5941. doi: 10.1016/j.bmcl.2012.07.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmcl.2012.07.060</ArticleId>
            <ArticleId IdType="pmc">PMC3433560</ArticleId>
            <ArticleId IdType="pubmed">22910039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busch A.E., Herzer T., Wagner C.A., Schmidt F., Raber G., Waldegger S., Lang F. Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes. Mol. Pharmacol. 1994;46:750–753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7969055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unsöld B., Kerst G., Brousos H., Hübner M., Schreiber R., Nitschke R., Greger R., Bleich M. KCNE1 reverses the response of the human K+ channel KCNQ1 to cytosolic pH changes and alters its pharmacology and sensitivity to temperature. Pflügers Arch. Eur. J. Physiol. 2000;441:368–378. doi: 10.1007/s004240000434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004240000434</ArticleId>
            <ArticleId IdType="pubmed">11211125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peretz A., Degani N., Nachman R., Uziyel Y., Gibor G., Shabat D., Attali B. Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties. Mol. Pharmacol. 2005;67:1053–1066. doi: 10.1124/mol.104.007112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.104.007112</ArticleId>
            <ArticleId IdType="pubmed">15598972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brueggemann L.I., Mackie A.R., Martin J.L., Cribbs L.L., Byron K.L. Diclofenac Distinguishes among Homomeric and Heteromeric Potassium Channels Composed of KCNQ4 and KCNQ5 Subunits. Mol. Pharmacol. 2011;79:10–23. doi: 10.1124/mol.110.067496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.110.067496</ArticleId>
            <ArticleId IdType="pmc">PMC3014280</ArticleId>
            <ArticleId IdType="pubmed">20876743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amato G., Roeloffs R., Rigdon G.C., Antonio B., Mersch T., McNaughton-Smith G., Wickenden A.D., Fritch P., Suto M.J. N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. ACS Med. Chem. Lett. 2011;2:481–484. doi: 10.1021/ml200053x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml200053x</ArticleId>
            <ArticleId IdType="pmc">PMC4018159</ArticleId>
            <ArticleId IdType="pubmed">24900334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brueggemann L.I., Haick J.M., Cribbs L.L., Byron K.L. Differential Activation of Vascular Smooth Muscle Kv7.4, Kv7.5, and Kv7.4/7.5 Channels by ML213 and ICA-069673. Mol. Pharmacol. 2014;86:330–341. doi: 10.1124/mol.114.093799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.114.093799</ArticleId>
            <ArticleId IdType="pmc">PMC4152906</ArticleId>
            <ArticleId IdType="pubmed">24944189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Archer S.L., Huang J.M., Hampl V., Nelson D.P., Shultz P.J., Weir E.K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 1994;91:7583–7587. doi: 10.1073/pnas.91.16.7583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.91.16.7583</ArticleId>
            <ArticleId IdType="pmc">PMC44446</ArticleId>
            <ArticleId IdType="pubmed">7519783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barman S.A., Zhu S., Han G., White R.E. cAMP activates BKCa channels in pulmonary arterial smooth muscle via cGMP-dependent protein kinase. Am. J. Physiol. Cell. Mol. Physiol. 2003;284:L1004–L1011. doi: 10.1152/ajplung.00295.2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00295.2002</ArticleId>
            <ArticleId IdType="pubmed">12547730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y.-D., Garcia M.L. Interaction of agitoxin2, charybdotoxin, and iberiotoxin with potassium channels: Selectivity between voltage-gated and Maxi-K channels. Proteins Struct. Funct. Bioinform. 2003;52:146–154. doi: 10.1002/prot.10341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/prot.10341</ArticleId>
            <ArticleId IdType="pubmed">12833539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown D.A., Passmore G.M. Neural KCNQ (Kv7) channels. J. Cereb. Blood Flow Metab. 2009;156:1185–1195. doi: 10.1111/j.1476-5381.2009.00111.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2009.00111.x</ArticleId>
            <ArticleId IdType="pmc">PMC2697739</ArticleId>
            <ArticleId IdType="pubmed">19298256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldman A.M., Glasscock E., Yoo J., Chen T.T., Klassen T.L., Noebels J.L. Arrhythmia in Heart and Brain: KCNQ1 Mutations Link Epilepsy and Sudden Unexplained Death. Sci. Transl. Med. 2009;1:2ra6. doi: 10.1126/scitranslmed.3000289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3000289</ArticleId>
            <ArticleId IdType="pmc">PMC2951754</ArticleId>
            <ArticleId IdType="pubmed">20368164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y., Feletou M., Ku D.D., Man R.Y.K., Vanhoutte P.M. The calcium ionophore A23187 induces endothelium-dependent contractions in femoral arteries from rats with streptozotocin-induced diabetes. Br. J. Pharmacol. 2007;150:624–632. doi: 10.1038/sj.bjp.0706999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0706999</ArticleId>
            <ArticleId IdType="pmc">PMC2189770</ArticleId>
            <ArticleId IdType="pubmed">17245370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Münzel T., Feil R., Mülsch A., Lohmann S.M., Hofmann F., Walter U. Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3′,5′-Cyclic Monophosphate–Dependent Protein Kinase. Circulation. 2003;108:2172–2183. doi: 10.1161/01.CIR.0000094403.78467.C3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000094403.78467.C3</ArticleId>
            <ArticleId IdType="pubmed">14597579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauvert O., Lugnier C., Keravis T., Marthan R., Rousseau E., Savineau J.P. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. J. Cereb. Blood Flow Metab. 2003;139:513–522. doi: 10.1038/sj.bjp.0705277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0705277</ArticleId>
            <ArticleId IdType="pmc">PMC1573876</ArticleId>
            <ArticleId IdType="pubmed">12788811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 1998;62:PL309–PL318. doi: 10.1016/S0024-3205(98)00158-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0024-3205(98)00158-1</ArticleId>
            <ArticleId IdType="pubmed">9600334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandner P., Zimmer D.P., Milne G.T., Follmann M., Hobbs A., Stasch J.-P.  Reactive Oxygen Species. Volume 264. Springer; Cham, Switzerland: 2018. Soluble Guanylate Cyclase Stimulators and Activators; pp. 355–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/164_2018_197</ArticleId>
            <ArticleId IdType="pubmed">30689085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Brandish P.E., DiValentin M., Schelvis J.P.M., Babcock G.T., Marletta M.A. Inhibition of Soluble Guanylate Cyclase by ODQ. Biochemistry. 2000;39:10848–10854. doi: 10.1021/bi9929296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi9929296</ArticleId>
            <ArticleId IdType="pubmed">10978171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 1995;48:184–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7544433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stasch J.-P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiß U., et al.  NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212–215. doi: 10.1038/35065611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35065611</ArticleId>
            <ArticleId IdType="pubmed">11242081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhanakoti S.N., Gao Y., Nguyen M.Q., Raj J.U. Involvement of cGMP-dependent protein kinase in the relaxation of ovine pulmonary arteries to cGMP and cAMP. J. Appl. Physiol. 2000;88:1637–1642. doi: 10.1152/jappl.2000.88.5.1637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/jappl.2000.88.5.1637</ArticleId>
            <ArticleId IdType="pubmed">10797124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimokawa H., Flavahan N.A., Lorenz R.R., Vanhoutte P.M. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. J. Cereb. Blood Flow Metab. 1988;95:1197–1203. doi: 10.1111/j.1476-5381.1988.tb11756.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.1988.tb11756.x</ArticleId>
            <ArticleId IdType="pmc">PMC1854271</ArticleId>
            <ArticleId IdType="pubmed">3064855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norel X., de Montpreville V., Brink C. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: Effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 2004;74:101–112. doi: 10.1016/j.prostaglandins.2004.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.prostaglandins.2004.07.003</ArticleId>
            <ArticleId IdType="pubmed">15560119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozłowska H., Baranowska-Kuczko M., Schlicker E., Kozłowski M., Zakrzeska A., Grzęda E., Malinowska B. EP3 receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats. Pharmacol. Rep. 2012;64:1526–1536. doi: 10.1016/S1734-1140(12)70950-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1734-1140(12)70950-7</ArticleId>
            <ArticleId IdType="pubmed">23406763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tatulian L., Delmas P., Abogadie F.C., Brown D.A. Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine. J. Neurosci. 2001;21:5535–5545. doi: 10.1523/JNEUROSCI.21-15-05535.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.21-15-05535.2001</ArticleId>
            <ArticleId IdType="pmc">PMC6762632</ArticleId>
            <ArticleId IdType="pubmed">11466425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsvetkov D., Kaßmann M., Tano J.-Y., Chen L., Schleifenbaum J., Voelkl J., Lang F., Huang Y., Gollasch M. Do KV7.1 channels contribute to control of arterial vascular tone? J. Cereb. Blood Flow Metab. 2017;174:150–162. doi: 10.1111/bph.13665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13665</ArticleId>
            <ArticleId IdType="pmc">PMC5192887</ArticleId>
            <ArticleId IdType="pubmed">28000293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder B.C., Hechenberger M., Weinreich F., Kubisch C., Jentsch T.J. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J. Biol. Chem. 2000;275:24089–24095. doi: 10.1074/jbc.M003245200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M003245200</ArticleId>
            <ArticleId IdType="pubmed">10816588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S.-S., Ran Y.-J., Zhang D.-D., Li S.-Z., Zhu D. MicroRNA-190 Regulates Hypoxic Pulmonary Vasoconstriction by Targeting a Voltage-Gated K+ Channel in Arterial Smooth Muscle Cells. J. Cell. Biochem. 2014;115:1196–1205. doi: 10.1002/jcb.24771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.24771</ArticleId>
            <ArticleId IdType="pubmed">24446351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mondéjar-Parreño G., Barreira B., Callejo M., Morales-Cano D., Barrese V., Esquivel-Ruiz S., Olivencia M.A., Macías M., Moreno L., Greenwood I.A., et al.  Uncovered Contribution of Kv7 Channels to Pulmonary Vascular Tone in Pulmonary Arterial Hypertension. Hypertension. 2020;76:1134–1146. doi: 10.1161/HYPERTENSIONAHA.120.15221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15221</ArticleId>
            <ArticleId IdType="pubmed">32829658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang A.W., Yang R., Kurata H.T. Sequence determinants of subtype-specific actions of KCNQ channel openers. J. Physiol. 2017;595:663–676. doi: 10.1113/JP272762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP272762</ArticleId>
            <ArticleId IdType="pmc">PMC5285613</ArticleId>
            <ArticleId IdType="pubmed">27506413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hampl V., Huang J.M., Weir E.K., Archer S.L. Activation of the cGMP-dependent protein kinase mimics the stimulatory effect of nitric oxide and cGMP on calcium-gated potassium channels. Physiol. Res. 1995;44:39–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8789298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klinger J.R., Kadowitz P.J. The Nitric Oxide Pathway in Pulmonary Vascular Disease. Am. J. Cardiol. 2017;120:S71–S79. doi: 10.1016/j.amjcard.2017.06.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2017.06.012</ArticleId>
            <ArticleId IdType="pubmed">29025573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H., Vanderpool R.R., Wang J., Yuan J.X.-J. Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension. Pulm. Circ. 2017;7:569–571. doi: 10.1177/2045893217728261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2045893217728261</ArticleId>
            <ArticleId IdType="pmc">PMC5841892</ArticleId>
            <ArticleId IdType="pubmed">28895506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García M.L., Knaus H.G., Munujos P., Slaughter R.S., Kaczorowski G.J. Charybdotoxin and its effects on potassium channels. Am. J. Physiol. Physiol. 1995;269:C1–C10. doi: 10.1152/ajpcell.1995.269.1.C1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.1995.269.1.C1</ArticleId>
            <ArticleId IdType="pubmed">7543240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia M.L., Garcia-Calvo M., Hidalgo P., Lee A., MacKinnon R. Purification and Characterization of Three Inhibitors of Voltage-Dependent K+ Channels from Leiurus Quinquestriatus var. Hebraeus Venom. Biochemistry. 1994;33:6834–6839. doi: 10.1021/bi00188a012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi00188a012</ArticleId>
            <ArticleId IdType="pubmed">8204618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Candia S., Garcia M., Latorre R. Mode of action of iberiotoxin, a potent blocker of the large conductance Ca2+-activated K+ channel. Biophys. J. 1992;63:583–590. doi: 10.1016/S0006-3495(92)81630-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3495(92)81630-2</ArticleId>
            <ArticleId IdType="pmc">PMC1262182</ArticleId>
            <ArticleId IdType="pubmed">1384740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Vizcaino F., Cogolludo A., Mondejar-Parreño G. Transcriptomic profile of cationic channels in human pulmonary arterial hypertension. Sci. Rep. 2021;11:15829. doi: 10.1038/s41598-021-95196-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-95196-z</ArticleId>
            <ArticleId IdType="pmc">PMC8338963</ArticleId>
            <ArticleId IdType="pubmed">34349187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandegar M., Yuan J.X.-J. Role of K+ channels in pulmonary hypertension. Vasc. Pharmacol. 2002;38:25–33. doi: 10.1016/S1537-1891(02)00123-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1537-1891(02)00123-4</ArticleId>
            <ArticleId IdType="pubmed">12378819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morecroft I., Murray A., Nilsen M., Gurney A., Lean M. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. J. Cereb. Blood Flow Metab. 2009;157:1241–1249. doi: 10.1111/j.1476-5381.2009.00283.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2009.00283.x</ArticleId>
            <ArticleId IdType="pmc">PMC2743843</ArticleId>
            <ArticleId IdType="pubmed">19508393</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
